Figure 2
From: Long-term efficacy of imatinib mesylate in patients with advanced Tenosynovial Giant Cell Tumor
Response and follow up of imatinib mesylate in patients with locally advanced or recurrent diffuse-type TGCT. NED = No evidence of disease, AWD = Alive with disease.
